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Abstract
Objective: Two clobazam aqueous suspensions for paediatric
oral usage (5 mg/ml) were investigated to determinate its physi-
cochemical stability under different storage conditions.
Method: Formulations were stored at 4 and 25 ºC and the clo-
bazam content was determined by High Performance Liquid
Chromatography. Each sample was analyzed by triplicate at dif-
ferent time points (0, 7, 14, 28 and 56 days).
Results: Liquid suspensions were successfully formulated from
pure drug and commercially available tablets. In both cases,
samples showed suitable physical stability. Clobazam was che-
mically stable in aqueous suspension during the 56 days of the
study at the two storage temperatures. 
Conclusions: All the tried oral liquid formulations can be con-
served at 4 and 25 ºC at least 56-day period.
Suspensiones extratemporáneas de clobazam para uso
pediátrico preparadas a partir de tabletas disponibles
comercialmente y fármaco puro
Resumen
Objetivo: Dos suspensiones orales acuosas de clobazam para
uso pediátrico (5 mg/ml) fueron evaluadas para determinar su
estabilidad fisicoquimica bajo diferentes condiciones de alma-
cenamiento. 
Métodos: Las formulaciones fueron conservadas a 4 y 25 ºC y
el contenido de clobazam fue determinado mediante Cro-
matografía Líquida de Alta Performance. Cada una de las
muestras fue analizada por triplicado a diferentes tiempos (0,
7, 14, 28 y 56 días). 
Resultados: Las suspensiones fueron formuladas satisfactoria-
mente a partir del principio activo puro y de comprimidos
disponibles comercialmente. En ambos casos, las muestras pre-
sentaron una adecuada estabilidad física. El clobazam fue
químicamente estable en las suspensiones acuosas durante los
56 días de duración del estudio a las dos temperaturas elegidas
para su conservación. 
Conclusiones: Todas las formulaciones orales líquidas formu-
ladas y evaluadas en este estudio pueden ser conservadas a 4 y
25 ºC por al menos 56 días. 
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Introduction
Epilepsy is a chronic neurological disorder which af-
fects between 0.5% and 1.0% of paediatric population1.
It involves recurrent unprovoked seizures and it is the
third most frequent neurological disorder, after cerebro-
vascular disease and dementia2. Typical pharmacological
treatment includes antiepileptic drugs (AEDs) that control
seizures when they are daily administered3. Unfortuna-
tely one fifth of children develop Intractable Childhood
Epilepsy4 where seizures became resistant to pharmaco-
logical control. Between the AEDs administered, cloba-
zam (CLB) is a 1,5-benzodiazepine (figure 1) which pre-
sents anticonvulsant pharmacological properties5 widely
used for adjunctive therapy on epilepsy treatment6. Ac-
tually, it is approved for clinical use as an AED in more
than one hundred countries1. Also it has been recently
approved by The US Food and Drug Administration as
add-on therapy for seizures associated with Lennox-Gas-
taut syndrome7. CLB has been effective against a broad
spectrum of seizure types in most patients for both short-
term and long-term treatment8. Even more, CLB resulted
useful in refractory seizures control9. Due to its unique
chemical structure, in comparison with the traditional
1,4-benzodiazepines, a reduction on its anxiolytic proper-
ties and collateral effects is observed1. Its major metabolite
in humans is N-desmethylCLB which is pharmacologically
active5. CLB is excreted unchanged and as metabolites
mainly in the urine.
CLB is a white or almost white crystalline powder
which is slightly soluble in water10. It is well absorbed after
oral ingestion and it presents a high oral bioavailability.
Usually, oral dose recommended for children, between 1
month and 12 years, is between 0.5 and 1.0 mg/kg/day11.
It is currently available as 10 and 20 mg tablets but un-
fortunately, no suitable liquid formulation for paediatric
administration is commercially available12.
The lack of paediatric liquid dosage forms represents
a challenge for hospital and community pharmacists.
Usually, children require smaller doses than adults which
are adjusted by body weight. Thereby solid dosage forms
must be fractionated in order to fit paediatric dosages.
This practice represents a concern issue because correct
dosing must be ensured13. Preparing extemporaneous li-
quid formulations using tablets is one of the most com-
mon practices employed to adjust doses for paediatric
patients. More over, children under 7 years old are una-
ble to swallow capsules or tablets. Liquid formulations
which are flavored aqueous solutions, syrups, or suspen-
sions, are administered directly into the child’s mouth by
drop, spoon, or oral dispenser or incorporated into the
child’s food14. General dose volumes are ≤5 ml for chil-
dren under 5 years and ≤10 ml for those of 5 years and
over15.
Among paediatric pharmacy practice, traditional com-
pounding techniques have become a useful tool in order
to develop not commercially available liquid dosage
forms16,17. In this context, liquid formulations facilitate
oral administration and enhance children treatment ad-
herence. An appropriate design of a liquid dosage form
requires not only a comprehensive analysis of chemical
and physical considerations of drugs and pharmaceutical
excipients but also evaluation of drug stability in the mid-
long term as well as drug effectiveness, tolerance and
formulation safety16.
The purpose of this study was to prepare an optimal
paediatric extemporaneous oral liquid CLB suspension
from commercially available tablets and pure drug to de-
termine the physical and chemical stability of these pro-
ducts for up to 56 days, stored at 4 and 25 °C. In this
way, these formulations allowed to study the compoun-
ding techniques versatility on developing liquid CLB do-
sage forms starting from different sources. In addition to
the best of our knowledge, no studies have been publis-
hed describing physical and chemical stability of an oral
CLB suspension.
Materials and methods
Materials 
Clobazam tablets (Sanofi – Aventis, batch: 707173)
were obtained from Hospital pharmacy (Paediatric Hospi-
tal J.P. Garrahan, Buenos Aires, Argentina) and clobazam
(Parafarm batch: E9A001) was purchased from Saporitti
(Buenos Aires, Argentina). Methylparaben (Nipagin) 
(D. Prest, batch: 20080325), propylparaben (Nipasol)
(D.Chutrau, batch: LI1814), saccharin sodium (Stanton,
batch: 40704), strawberry essence (D. Prest, batch 8410),
glycerin (D. Prest, batch: 090505), sorbitol solution, 70%
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Figure 1. Chemical structure of clobazam.
04. ORIGINALES. Extemporaneous_Farm Hosp  02/04/13  13:14  Página 104
(Van Rossum SRL, batch 808181760), carboxymethylce-
llulose sodium (CMC sodium) of high viscosity (Parafarm,
batch: 508081) and solvents of HPLC grade were used as
received. 
Formulations preparation
In the present study we prepared two CLB suspensions
denominated Formulation A and B: 
— CLB (pure drug) 0.5 %w/v and CMC sodium
1 %w/v (Formulation A). 
— CLB commercial tablets (equivalent to 0.5 %w/v of
CLB) and CMC sodium 0.7 %w/v (Formulation B). 
The rest of pharmaceutical excipients for each formu-
lation are detailed in table 1. The suspensions were pre-
pared as follows: 
Formulation A
First, nipagin and nipasol were solubilized in ¼ total
volume of distilled water at 90 °C. Once the preservative
agents were dissolved, the solution was cooled and sac-
charin sodium was added. Separately, CLB (pure drug)
was placed into a mortar and triturated with CMC so-
dium. Next a right amount of glycerin, containing the
strawberry essence, was added in a constant shaking un-
til a homogeneous smooth paste is formed. After the
glycerin incorporation is completed, CLB was completely
dispersed. In the next place, sorbitol 70% and the pre-
servative agent solutions were both incorporated to the
previous suspension and homogenized. 
Finally, the suspension volume was brought to 100 ml
with distilled water. Later CLB suspension was shaken un-
til homogeneity. The formulations were conserved in am-
ber glass vials under refrigeration (4 ºC) and controlled
room temperature (25 ºC), in the absence of light. Before
removing the samples, containers were agitated to en-
sure uniform re-dispersion of the content. At least three
batch of every formulation were prepared.
Formulation B
The same technique was followed as Formulation A.
In this case, CLB tablets were grinded to fine powder in
a mortar before use.
The elaborated suspensions were physical and chemi-
cal characterized as we describe below.
HPLC assay 
Clobazam content of formulations were tested by
High Performance Liquid Chromatography (HPLC). The li-
quid chromatographic system consisted of an isocratic
solvent delivery pump (Shimadzu LC-20AT) which pum-
ped a mixture of 50% acetonitrile and 50% water
through a 125 mm ¥ 4 mm reversed-phase C-18, 5-µm
column (LiChrospher® 100 RP-18, LiChroCART® 125-4)
at 1.0 ml/min. The column was maintained at room tem-
perature. The samples (20 µl) were introduced into the li-
quid chromatographic system using an injector (Rheo -
dyne 7725i). The column effluent was monitored with a
variable wavelength ultraviolet detector (Waters 486) at
290 nm. The analytical method was carried out accor-
ding to the specifications in British Pharmacopoeia 98.
Stock CLB solutions were prepared by dissolving the drug
in methanol (50 µg/ml). Linearity was evaluated by analy-
zing a set of CLB solutions ranging from 10 to 400 µg/ml
(R2 0.9998). The specificity of the analytical method in
the presence of pharmaceutical additives and CLB degra-
dation products was evaluated from CLB stock solution
(50 µg/ml) and pharmaceutical additives solution without
CLB. Both were subjected to forced acidic degradation
(1N HCl), basic degradation (1N NaOH) and oxidation
(10% H2O2) at 100 °C for 45 minutes. Aliquots were neu-
tralized and filtered (0.45 m cellulose nitrate membra-
nes, Whatman® GmbH, Germany) before being analyzed.
pH determination
The apparent pH was determined at 0, 28 and 56 days.
Examination was conducted with a digital pH-meter IQ 140
(IQ Scientific Instruments, CA, USA). Each measurement
was done by triplicate and then the results were averaged.
Sedimentation volume
A suitable parameter, for assessing the physical stabi-
lity of a suspension, is the sedimentation volume which
is defined as: 
Vs= Vf/V0,
Where Vs is the volume ratio, Vf and Vo are the final
settled volume and the original suspension volume, res-
pectively. In the present study, samples (50 ml) were hand
shaked for 30 seconds in order to asses the content uni-
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Table 1. Excipients used in CLB suspensions
(formulation A and B)
Formulation
Pharmaceutical Functional (% w/v)
excipient Category A B
CMC sodium Suspending agent 1.00 0.70
Glycerin Humectant 5.00
Sorbitol 70% solution Humectant and sweetening agent 35.00
Nipagin Antimicrobial preservative 0.07
Nipasol Antimicrobial preservative 0.03
Saccharin sodium Sweetening agent 0.40
Strawberry essence Flavoring agent 0.10
Distilled water Vehicle q.s
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formity and transferred from amber glass vials to a 50 ml-
graduated cylinder protected from light and sealed with a
rubber cap. Then, Vs was determined after samples were
allowed to stand for 56 days at 4 and 25 °C. Assays were
done by triplicate and then the results were averaged. 
Viscosity determination
Viscosity, which is the inverse of fluidity, could vary af-
ter storage at different conditions. Thereby, samples (150
ml) dynamic viscosity was tested with a Brookfield Rota-
tional Viscometer RVT- Spindle #2 (Massachusetts, USA)
at 1, 2.5, 5, 10, 20 and 50 RPM, with time intervals of 60
seconds, at day 0, 28 and 56. Viscosity was measured
three times in units of milliPascal ¥ seconds (mPa.s) and
the results were averaged.
Stability study
In order to evaluate CLB chemical stability under diffe-
rent storage conditions, CLB suspensions were storage at
4 and 25 °C in amber, glass vials (30 ml) in the absence
of light. Then, aliquots were collected from each contai-
ner on days 0, 3, 7, 14, 28 and 56. Samples were pro-
perly diluted (50 µg/ml) with HPLC mobile phase in order
to fit the calibration range curve and immediately analy-
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Figure 2. Chromatograms
showing to the suspension
without CLB (A), CLB stan-
dard (B), CLB subjected to
acid degradation (C).
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zed by HPLC. CLB stability in each liquid formulation was
determined by calculating the percentage of the initial
CLB concentration remaining at each time point. Stability
was defined as the retention of not less than 90% of the
initial concentration.
Morphology
The morphological analysis of CLB suspended particles
was conducted by means of optical microscopy (Trinocu-
lar Microscope Arcano XSZ-107 E) with photographic di-
gital camera. The photos were analyzed using TSView
Version 6.2.4.5 for Windows.
Results
Preliminary studies investigated the development of
CLB solution with a high concentration of co-solvent
such as propylene-glycol (60 %v/v) and sorbitol 70% so-
lution (30 %v/v), in order to enhance CLB aqueous solu-
bility. However, CLB extemporaneous solution presented
low physical stability and drug remaining in solution only
for 7 days. Also, formulations with lower concentration
of propylene-glycol presented drug precipitation at 48 h.
Therefore, an aqueous suspension results a useful do-
sage form for administering a water-poorly soluble or
aqueous-chemical unstable drug. This is the main reason
why suspension development appears as an excellent 
approach for CLB liquid formulation containing a quan-
tity of drug in an acceptable volume13,18-21. Also, suspen-
sions could mask CLB unpleasant taste improving paedia-
tric formulation acceptance and treatment adherence.
The figure 2 shows the chromatograms corresponding
to the suspension without CLB (A), CLB standard solution
(50 µg/ml) (B), CLB subjected to acid degradation (C),
CLB subjected to alkaline degradation (D) and CLB sub-
jected to oxidation (E). The CLB retention time was 3.48
min. The relative error and the CV (coefficient of varia-
tion) were lower than 10%. It was shown that the analy-
tical method was able to separate the CLB peak of the
degradations peaks and there was no interference bet-
ween CLB standard, degradation products and suspen-
sion control retention times. 
To assess the CLB stability in paedriatic oral formula-
tions, extemporaneous oral liquid CLB suspensions from
commercially available tablets and pure drug were assa-
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yed. These suspensions were prepared with excipients
commonly used in paediatric formulations22 and they
were stored at two different temperatures (4 and 25 ºC)
for 56 days. In both cases, suspensions were easily re-dis-
persed after simple hand-shaking (30 seconds) and pH
values did not show an important variation along the as-
say (table 2). However, the Vs increased between 0 and
56 days, for both storage temperatures (table 3). Notice
that formulations stored at 4 ºC showed lower Vs values
than their counterparts stored at 25 ºC for 28 and 56 days.
Figure 3 shows the dynamic viscosity as a function of
the rotational speed, for samples A and B. Both, the up-
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Figure 3. Viscosity of
CLB suspensions prepa-
red from pure drug (A)
and commercially avai-
lable tablets (B). 
Table 2. pH of CLB suspensions (formulation A and B)
stored at 4 and 25 °C. For two temperatures (n = 3)
Temperature pH
Formulation (°C) day 0 day 28 day 56
A
4 6.68 ± 0.03 6.65 ± 0.05 6.76 ± 0.08
25 6.68 ± 0.03 6.65 ± 0.04 6.69 ± 0.07
B
4 6.85 ± 0.04 6.85 ± 0.06 6.94 ± 0.10
25 6.85 ± 0.04 6.83 ± 0.07 6.95 ± 0.10
Table 3. Vs of CLB suspensions (formulation A and B)
stored at 4 and 25 °C. For two temperatures (n = 3)
Temperature Vs
Formulation (°C) day 28 day 56
A
4 0.025 0.043
25 0.035 0.043
B
4 0.057 0.067
25 0.082 0.091
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ward and downward curves, presented identical path-
ways which suggested a pseudoplastic flow without thi-
xotropy. Also, a difference could be observed between
formulation A and B viscosity values. Formulation B sho-
wed a higher viscosity values than formulation A. 
Formulation A showed an increase on viscosity values af-
ter 28 and 56 days under refrigerated conditions (4 ºC). Ho-
wever, the samples viscosity was reduced when the storage
was perform at 25 ºC (table 4). A similar trend was followed
by formulation B. Nevertheless, the viscosity variation at 4 ºC
was less marked and values remain almost unchanged.
According to the chemical characterization, CLB stabi-
lity was followed by HPLC. Table 5 shows the initial CLB
concentration remaining percentage up to 56 days. En-
couraging results were obtained for both formulations as
to CLB chemical stability. Formulations (A and B) presen-
ted a CLB remaining percentage above 98% for both
storage conditions (4 and 25 ºC).
The morphological characterization of the suspended
CLB particles is showed on figure 4. Notice the presence
of irregular CLB particles and the higher amount of sus-
pended particles in formulation B (figure 4B). 
Discussion
The aim of the present study was to develop an opti-
mal oral liquid CLB suspension in order to enhance physi-
cal-chemical stability of the drug and paediatric patient
acceptance.
As it is well known, suspensions are thermodynamic
unstable systems. Therefore, suspended particles would
sediment at a certain sedimentation velocity. That is the
main reason why they have to be shaken before use, to
ensure content uniformity19. According with the Stocks
Law23, changes on viscosity values could modify sedimen-
tation velocity of the suspended particles. Generally, sus-
pending vehicles are used to maintain dispersed particles
homogeneously distributed in the formulation by kee-
ping an appropriate viscosity. Our formulations presented
a pseudoplastic flow because the hydrocolloid used as
suspending agent was CMC sodium which imparts non-
Newtonian properties to the suspension. This is very im-
portant because a pseudoplastic dispersion media could
support two processes: 1) retard the sedimentation of
small particles, as their apparent viscosities increase under
the small stresses associated with sedimentation, and 2) the
medium could undergo structural breakdown under
the higher stresses involved in shaking and pouring24.
Although the suspending vehicule content was reduced
from 1 to 0.7 %w/v. Formulation B showed a higher vis-
cosity values than A, probably due to the amount of phar-
maceutical excipients presented on commercial tablets. 
As to our results, refrigerated storage conditions (4 °C)
produced a slight increase on formulation viscosity lea-
ding to a decrement on sedimentation velocity of the
suspended particles. Cancela et al25 observed that the vis-
cosity of suspensions containing CMC sodium decreases
when the temperature increases. This behaviour agrees
with our results. Therefore, Vs values at 4 °C resulted
smaller than those for samples storage at room contro-
lled temperature for a period of 56 days. 
One of the main objectives of the present work was to
investigate CLB chemical stability under different storage
conditions. Both kinds of formulations (A and B) demons-
trated an acceptable drug chemical stability where CLB
content remain above 98% at room controlled tempera-
ture and refrigerator temperature for a period of 56 days.
As to the microscopic aspect of the samples, those
prepared from commercially available tablets present a
higher amount of suspended particles due to the pre-
sence of water-insoluble pharmaceutical additives in the
Extemporaneous clobazam suspensions for paediatric use prepared… Farm Hosp. 2013;37(2):103-110 - 109
Figure 4. Microphoto-
graphs of CLB suspen-
sions prepared from pure
drug (A) and commer-
cially available tablets (B).
Scale bar: 17 µm.
Table 4. Viscosity of CLB suspensions (formulation A 
and B) stored at 4 and 25 °C. For two temperatures (n = 3)
Temperature pH
Formulation (°C) day 0 day 28 day 56
A
4 828.3 ± 30.1 887.5 ± 30.5 911.7 ± 24.5
25 828.3 ± 30.1 757.5 ± 23.5 696.7 ± 30.5
B
4 973.3 ± 35.1 957.5 ± 33.5 975.0 ± 32.0
25 973.3 ± 35.1 912.5 ± 30.5 865.0 ± 32.0
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CLB tablets. Nevertheless, the same morphology of CLB
particles was observed for both kinds of formulations (fi-
gure 4).
In conclusion, paediatric oral liquid CLB suspensions
presented an adequate physical stability in order to keep
the CLB particles homogeneously distributed in the for-
mulation. The adequate chemical CLB stability under re-
frigerated and room controlled temperature conditions
are of real importance, since CLB suspensions could easily
be distributed and storage at a paediatric hospital wi-
thout any special storage conditions. 
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Table 5. Stability of CLB suspensions (formulation A and B) stored at 4 and 25 °C. For two temperatures (n = 3)
Temperature % Initial concentration remaining*
Formulation (°C) day 0 day 7 day14 day 28 day 56
A
4 101.3 ± 0.1 103.8 ± 1.3 103.6 ± 1.8 103.3 ± 4.7 99.2 ± 2.8
25 101.3 ± 0.1 99.2 ± 2.3 102.1 ± 2.4 109.9 ± 2.6 98.8 ± 7.7
B
4 103.4 ± 1.7 103.3 ± 1.7 103.9 ± 1.9 107.8 ± 0.5 100.4 ± 2.8
25 103.4 ± 1.7 101.0 ± 0.5 104.7 ± 0.5 110.2 ± 1.2 102.0 ± 2.0
*The mean values ± S.D.
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